Journal of Clinical Oncology
Articles in this Issue
Reply to: “Is Dual-Checkpoint Blockade Beneficial Beyond Prolonging Chemoradiotherapy-to-Surgery Interval in Rectal Cancer?” and “Dual Immunotherapy in the Neoadjuvant Interval for Locally Advanced Rectal Cancer: A New Hope?”
AAML1831: A Phase III Trial Comparing Standard Induction Therapy With CPX-351 in De Novo Pediatric AML: A Report From the Children's Oncology Group
PURPOSE The Children's Oncology Group phase III clinical trial AAML1831 (ClinicalTrials.gov identifier: NCT04293562...
Into the Unknown: Regulatory Perspective on Identifying Optimized Dosages of Oncology Radiopharmaceutical Therapies
Post-Recurrence Therapy After Hepatectomy: Clarifying Overall Survival in JCOG0603
Total Neoadjuvant Therapy With Long-Course Radiotherapy Versus Chemoradiotherapy in High-Risk Locally Advanced Rectal Cancer (TNTCRT): A Multicenter, Randomized, Phase III Trial
PURPOSE High-risk locally advanced rectal cancer (LARC) carries a substantial risk of distant recurrence, which limits disease-free survival (DFS). We compared total neoadjuvant th...
Reply to: Post-Recurrence Therapy After Hepatectomy: Clarifying Overall Survival in JCOG0603
Corticosteroids in Glioblastoma Management: A Reconsideration of a 65-Year Practice
Reply to: Precision in Proximity: The Radiation Oncologist's Perspective on Tailoring Total Neoadjuvant Therapy by Rectal Tumor Location
Precision in Proximity: The Radiation Oncologist's Perspective on Tailoring Total Neoadjuvant Therapy by Rectal Tumor Location
International Myeloma Working Group Recommendations for the Diagnosis and Management of Solitary Plasmacytomas
Solitary plasmacytomas (SPs) are rare localized tumors of clonal plasma cells, either in the bone (solitary bone plasmacytoma) or in soft tissue/extraosseous (extramedullary) with either no or with mi...
Thrombopoietin Receptor Agonists for Chemotherapy-Induced Thrombocytopenia in GI Cancers—A Big Solution for a Small Problem or a Solution at All?
Are Radiopharmaceutical Therapy Trials Designed to Undertreat?
Optimizing Outcomes After Pediatric Haploidentical Donor Transplant: Role of Graft-Versus-Host Disease Prophylaxis?
Reply to: Optimizing Outcomes After Pediatric Haploidentical Donor Transplant: Role of Graft-Versus-Host Disease Prophylaxis?
Durvalumab With Radiation Therapy in Patients With Inoperable Locally Advanced Non–Small Cell Lung Cancer Ineligible for Concurrent Chemoradiotherapy (DART)
PURPOSE Concurrent platinum-based chemotherapy and radiation therapy (cCRT) followed by consolidative durvalumab is the standard of care (SoC) for fit patients with inoperable, loc...
Breast Cancer Follow-Up and Surveillance After Primary Treatment: ASCO Guideline Update
PURPOSE To offer clinicians recommendations concerning breast cancer follow-up and surveillance after primary treatment. M...
Clinical and Psychological Outcomes After Monoclonal Gammopathy Screening: A Population-Based Screening Study and Subsequent Randomized Trial of Follow-Up
Multiple myeloma (MM) and related malignancies develop from an asymptomatic precursor condition, monoclonal gammopathy of undetermined significance (MGUS), detectable via blood testing. The benefits a...
Rituximab Maintenance Added to Ibrutinib-Containing Therapy in Younger, Untreated Patients With Mantle Cell Lymphoma: Results From the TRIANGLE Trial
The TRIANGLE trial established an ibrutinib-containing therapy without autologous stem-cell transplantation (ASCT) as the new standard for younger, treatment-naïve patients with mantle cell lymphoma (...
Avatrombopag Versus Placebo for Persistent Chemotherapy-Induced Thrombocytopenia in GI Cancers: The Phase II ACT-GI Trial
PURPOSE Chemotherapy-induced thrombocytopenia (CIT) is a challenging and common complication of cytotoxic chemotherapy in patients with GI cancers. There is no widely available app...
Magrolimab Plus Azacitidine Versus Placebo Plus Azacitidine in Patients With Untreated Higher-Risk Myelodysplastic Syndromes: The Phase III ENHANCE Study
PURPOSE To evaluate the efficacy and safety of the cluster of differentiation 47–targeted antibody magrolimab plus azacitidine (Magro/Aza) versus azacitidine...
Current Management of Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer in a Changing Landscape
Over the past three decades, the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer has undergone a remarkable transformation. Once associated with poor outcomes and a...
Systemic Treatment of Ovarian Cancer Recurrence: ASCO Living Guideline, Version 2026.1.0
PURPOSE To provide guidance regarding the systemic treatment of patients with high-grade serous and/or endometrioid epithelial ovarian, fallopian tube, or primary peritoneal cancer...